AJ2016 schreef op 24 november 2016 18:38:
[...]
Declan, het stuk dat ik uit de prospectus plaatste gaat ook in op onzekerheden omtrent betaling aan Valeant. Sterker nog, Pharming wijdt een heel stuk aan wat er in dat geval gaat gebeuren. Bijvoorbeeld:
If the Transaction does not close, the available net cash (cash and cash equivalents) at the date of the Prospectus is not expected to deplete before the end of March 2018. Pharming generates insufficient cash from commercial activities to meet all its
present and future anticipated requirements and remains dependent on financing arrangements with third parties as has been the case since its incorporation, but currently has sufficient cash reserves and sales revenues including current growth to be confident that it will be able to meet all its obligations as they fall due until at least the end of March 2018.
Voor de goede orde. Transaction slaat hierop: Pharming and Valeant have agreed that the Company will acquire all commercialisation rights to its own product RUCONEST® in North America (USA, Canada and Mexico) from Valeant (the Transaction).